US-based drug discovery technology provider Schrödinger has partnered with Canada’s Centre for Drug Research and Development (CDRD) to create new cancer biologics, including immuno-oncology monoclonal antibodies.
The CDRC will supply targeted antibodies, which will be analysed by Schrödinger using its computation platform to prioritise the drug candidates and, if needed, enhance discovery.
Initially, the companies plan to work on an immune checkpoint target found on cancer stem cells.
Schrödinger president and CEO Ramy Farid said: “We’re excited to work with CDRD to aggressively translate scientific discoveries into innovative therapeutic products.
“This partnership is an important step forward in our efforts to extend the successes we’ve had in small molecule drug discovery to the development of novel biologics.”
As per the agreement, Schrödinger will predict physico-chemical liabilities and antibody humanisation in order to support hit triage and prioritisation, while CDRD will deliver critical molecular and physicochemical measurements for the antibody portfolio.
CDRD president and CEO Gordon McCauley said: “Schrödinger is the leader in applying in silico modelling to small molecule drug discovery, and we are excited to be a part of this unique collaboration leveraging those capabilities to speed biologics discovery.
“This collaboration also highlights our partnership with BCCA and our collaborative approaches as we work to advance groundbreaking cancer research from bench to bedside.”